Search
Powered By HealthLine
Health Tools
 Arthritis Questions and Answers
 Arthritis Symptom Checker
 Arthritis Drug Information
 Preventing Arthritis
 Arthritis Treatment
Featured Conditions
 Osteoarthritis
 Chronic Pain
 Rheumatoid Arthritis
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Actos

[Pioglitazone]

Ethnicity:

Pharmacokinetic data among various ethnic groups are not available.

Drug-Drug Interactions

Text Continues Below



The following drugs were studied in healthy volunteers with a co-administration of ACTOS 45 mg once daily. Listed below are the results:

Fexofenadine HCI:
Co-administration of ACTOS for 7 days with 60 mg fexofenadine administered orally twice daily resulted in no significant effect on pioglitazone pharmaco-kinetics. ACTOS had no significant effect on fexofenadine pharmacokinetics.

Glipizide:
Co-administration of ACTOS and 5 mg glipizide administered orally once daily for 7 days did not alter the steady-state pharmacokinetics of glipizide.

Digoxin:
Co-administration of ACTOS with 0.25 mg digoxin administered orally once daily 7 days did not alter the steady-state pharmacokinetics of digoxin.

Warfarin:
Co-administration of ACTOS for 7 days with warfarin did not alter the steady-state pharmacokinetics of warfarin. ACTOS has no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy.

Metformin:
Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.

Midazolam:
Administration of ACTOS for 15 days followed by a single 7.5 mg dose of midazolam syrup resulted in a 26% reduction in midazolam Cmax and AUC.

Ranitidine HCI:
Co-administration of ACTOS for 7 days with ranitidine administered orally twice daily for either 4 or 7 days resulted in no significant effect on pioglitazone pharmacokinetics. ACTOS showed no significant effect on ranitidine pharmacokinetics. ER: Co-administration of ACTOS for 7 days with 30 mg nifedipine ER adminis-tered orally once daily for 4 days to male and female volunteers resulted in least square mean (90% Cl) values for unchanged nifedipine of 0.83 (0.73-0.95) for Cmax and 0.88 (0.80-0.96) for AUC. In view of the high variability of nifedipine pharmacokinetics, the clinical significance of this finding is unknown.

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>







HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire